Trial Profile
Safety and efficacy of thymoglobulin (ATG) for cord blood transplantation for hematologic malignancies.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2018
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 05 Dec 2018 Status changed from recruiting to discontinued.
- 08 Apr 2011 New trial record